Dr. Raza Bokhari
Executive Co-Chairman of the Board and CEO
Dr. Raza Bokhari joined the board of FSD Pharma in August 2018 and was named Executive Co-Chairman of the Board in December, Interim CEO in February 2019 and Permanent CEO in June 2019. Dr. Bokhari has been responsible for developing and leading FSD’s strategic vision into synthetic cannabinoid platforms.Learn More »
Executive Co-Chairman of the Board and Founder
Anthony Durkacz is currently a Director and Executive Vice President at First Republic Capital Corporation, which he joined in January 2014. First Republic has acted as the exclusive agent of the company and has raised approximately $53 million of equity capital to date.Learn More »
President, Founder and Director
Zeeshan Saeed is President and Director of FSD Pharma. As co-founder, of FV Pharma, now wholly owned by FSD, he has been involved with the company from the earliest stages. Mr. Saeed provided consulting advice to FV Pharma and was instrumental for raising the initial seed capital. He played a key role in bringing together a team of professionals in the development of the Corporation business plan as well as bringing key relationships to the company.Learn More »
Donal Carroll, CPA
Interim Chief Financial Officer
Donal Carroll joined FSD Pharma as Chief Financial Officer in 2018. An experienced business executive, he has 20 years of corporate finance leadership and public company experience, as well as deep expertise in syndicate investing both in equity and debt securities. Mr. Carroll is also Chief Financial Officer of World Class Extractions Inc. With a balance of prudent financing practices and unique insights, Mr. Carroll has successfully guided companies for expansion and growth.Learn More »
Dr. Sara May, Ph.D.
President, FV Pharma Inc.
Dr. Sara May is a Ph.D. graduate with a multidisciplinary background in plant breeding and crop genetics with over ten years’ experience designing, implementing and managing large-scale projects in the field, lab and greenhouse. She has extensive work experience with all aspects of National, International, Provincial and Regional Legislative Acts and Regulations. Dr. May has deep domain expertise in the Medical Cannabis industry, which includes managing large scale operations, developing and implementing quality control and quality assurance methods and standard operating procedures and HACCP.Learn More »
Dr. Edward Brennan, Jr., M.D., FACS
President, FSD Pharma BioSciences Division
Dr. Edward J. Brennan, Jr., M.D., FACS has more than 25 years of experience in leadership roles at major pharmaceutical companies and clinical research organizations. He is an accomplished biopharmaceutical executive with a proven track record in FDA submissions and drug development.Learn More »
Head of Communications and Investor Relations
Sandy Huard is a marketing and communications executive, senior strategist and consultant with over 21 years of marketing and sales experience leading national marketing teams, driving sales performance and launching national brands in the financial services industry.Learn More »
Scientific Advisory Board
Dr. Charles V. Pollack, Jr., M.A., M.D., FACEP, FAAEM, FAHA, FACC, FESC, FCPP
Chairman of Scientific Advisory Board
Dr. Charles Pollack is an international leader in emergency medicine and has been active in teaching and clinical research. He is the only physician to have received the American College of Emergency Physicians’ highest national awards in both teaching and research; he also received the national teaching award from the Council of Emergency Medicine Residency Directors. He is the only US emergency physician to be elected a Fellow of the European Society of Cardiology. His primary emergency care research interests are in the management of thrombosis, reversal of anticoagulation, infectious disease emergencies, and treatment of pain.Learn More »
Dr. Daniel Piomelli, Ph.D.
Dr. Piomelli is the Louise Turner Arnold Chair in Neurosciences and Distinguished Professor of Anatomy and Neurobiology, Pharmacology and Biological Chemistry at the University of California, Irvine, where he is also the Director of the Center for the Study of Cannabis. He has authored more than 400 peer-reviewed articles in high-impact journals, three full-length books and 34 patents and founded the Department of Drug Discovery and Development at the Italian Institute of Technology in Genoa, Italy, which he directed from 2007 to 2016. He is Editor-in-Chief of Cannabis and Cannabinoid Research, the only peer-reviewed journal entirely dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the endocannabinoid system.
Dr. Ryan Vandrey, Ph.D.
Dr. Vandrey is an experimental psychologist and an Associate Professor at the Behavioral Pharmacology Research Unit at Johns Hopkins University. Dr. Vandrey’s research focuses primarily on the impact of route of administration, dose, and chemical composition of cannabis products on resultant drug effects and pharmacokinetics. In addition, Dr. Vandrey has been involved with a broad range of studies related to the risks and benefits of medicinal cannabis use, the effects of cannabis use on sleep, cannabis withdrawal and the treatment of Cannabis Use Disorder, cannabis product testing, and developing measures of cannabis use behavior.
Dr. Ziva Cooper, Ph.D.
Dr. Cooper is the Research Director of UCLA’s Cannabis Research Initiative in the Semel Institute for Neuroscience and Human Behavior in the Department of Psychiatry and Biobehavioral Sciences.Learn More »
Dr. Mallory Loflin, Ph.D.
Dr. Loflin is a research scientist for Veterans Affairs San Diego Healthcare System (VASDHCS) and an Assistant Professor of Psychiatry within the University of California, San Diego (UCSD) School of Medicine.Learn More »
Board of Directors
Robert J. Ciaruffoli, CPA
Robert J. Ciaruffoli is a co-founder and vice-chairman of Broad Street Angels, a 100 member Philadelphia based angel investor network which invests in start-up entrepreneurial businesses with high growth potential. Broad Street Angels is the largest angel investor network in the Philadelphia region.Learn More »
James A. Datin
Over the course of his 30+ year career, James A. Datin has been a successful CEO, raised capital for entrepreneurs to grow companies, and has managed companies throughout the United States, Europe and Asia. He has also completed more than 50 transactions including venture investments, buyouts, acquisitions, mergers, IPOs, licensing and partnership agreements.Learn More »
Gerald Goldberg, CPA, CA
Gerald Goldberg, CPA, CA, has over 30 years of experience in the service, distribution, retail, mining, natural resources and oil & gas, real estate, not-for-profit entities and manufacturing industries, with a strong emphasis in taxation and business advisory services.Learn More »
David Urban joined the FSD Pharma Board of Directors in November 2018. He is a driven leader and board member with comprehensive accomplishments leading corporate development, government affairs, coalitions, legislative influence and political campaigns. He currently serves as President of American Continental Group (ACG) one of Washington’s premier bipartisan government affairs and strategic consulting firms.Learn More »